Cardiac disease, chronic kidney and liver disease, and metabolic derangements such as type 2 diabetes (T2DM) and obesity do not exist in isolation — they share common etiologies, pathophysiologic mechanisms, and risk factors, and their management increasingly demands a unified, integrated approach. These novel insights and their therapeutic implications have been recognized and adopted by cardiology, nephrology, endocrinology, and hepatology alike.

Yet a need exists for a dedicated multidisciplinary scientific platform that unites all interested parties — bringing together primary care physicians, family doctors, and specialists in a single forum devoted to in-depth Cardiovascular, Renal, Liver, Metabolic, and Obesity (CaReMeLO) discussions.

The CaReMeLO Conference continues to spotlight the pivotal role of family physicians in the integrated management of cardio-renal-metabolic (CRM) syndrome, steatotic liver disease, and obesity, with an enhanced focus on the evolving therapeutic landscape — including SGLT2 inhibitors, GLP-1 receptor agonists, and the dual GIPR/GLP-1 receptor agonist class.